Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Archive ouverte

Sistigu, Antonella | Yamazaki, Takahiro | Vacchelli, Erika | Chaba, Kariman | Enot, David | Adam, Julien | Vitale, Ilio | Goubar, Aicha | Baracco, Elisa, E | Remédios, Catarina | Fend, Laetitia | Hannani, Dalil | Aymeric, Laetitia | Ma, Yuting | Niso-Santano, Mireia | Kepp, Oliver | Schultze, Joachim, L. | Tüting, Thomas | Belardelli, Filippo | Bracci, Laura | La Sorsa, Valentina | Ziccheddu, Giovanna | Sestili, Paola | Urbani, Francesca | Delorenzi, Mauro | Lacroix-Triki, Magali | Quidville, Virginie | Conforti, Rosa | Spano, Jean-Philippe | Pusztai, Lajos | Poirier-Colame, Vichnou | Delaloge, Suzette | Penault-Llorca, Frédérique | Ladoire, Sylvain | Arnould, Laurent | Cyrta, Joanna | Dessoliers, Marie-Charlotte | Eggermont, Alexander | Bianchi, Marco, E | Pittet, Mikael | Engblom, Camilla | Pfirschke, Christina | Préville, Xavier | Uzé, Gilles | Schreiber, Robert, D | Chow, Melvyn, T | Smyth, Mark, J | Proietti, Enrico | André, Fabrice | Kroemer, Guido | Zitvogel, Laurence

Edité par CCSD ; Nature Publishing Group -

International audience. The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs) 2. Moreover, intracellular pathogens generally trigger adaptive mechanisms aimed toward the re-establishment of homeosta-sis, including the unfolded protein response (UPR) and autophagy 3,4. In mammals, MAMPs coupled to the activation of stress responses Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of innate and T cell-mediated anticancer immune responses. Here we demonstrate that anthracyclines stimulate the rapid production of type I interferons (IFNs) by malignant cells after activation of the endosomal pattern recognition receptor Toll-like receptor 3 (TLR3). By binding to IFN- and IFN- receptors (IFNARs) on neoplastic cells, type I IFNs trigger autocrine and paracrine circuitries that result in the release of chemokine (C-X-C motif) ligand 10 (CXCL10). Tumors lacking Tlr3 or Ifnar failed to respond to chemotherapy unless type I IFN or Cxcl10, respectively, was artificially supplied. Moreover, a type I IFN-related signature predicted clinical responses to anthracycline-based chemotherapy in several independent cohorts of patients with breast carcinoma characterized by poor prognosis. Our data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens. We surmise that such 'viral mimicry' constitutes a hallmark of successful chemotherapy. npg

Consulter en ligne

Suggestions

Du même auteur

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Archive ouverte | Liu, Peng | CCSD

International audience. Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying hi...

CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy

Archive ouverte | Ma, Yuting | CCSD

International audience

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

Archive ouverte | Ma, Yuting | CCSD

International audience. The therapeutic efficacy of anthracyclines relies on antitumor immune responses elicited by dying cancer cells. How chemotherapy-induced cell death leads to efficient antigen presentation to ...

Chargement des enrichissements...